Patents by Inventor Stephen D. Swenson

Stephen D. Swenson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180353627
    Abstract: A method for suppressing or inhibiting the growth of a cancer cell or tumor cell that expresses one or more integrins on its cell surface in a subject in need thereof is disclosed, herein, the method comprising administering to the subject an effective amount of contortrostatin (CN) and/or vicrostatin (VCN) or an equivalent of each thereof and wherein the CN and/or VCN or the equivalent of each thereof is conjugated to a therapeutic radioisotope.
    Type: Application
    Filed: November 11, 2016
    Publication date: December 13, 2018
    Inventors: Thomas C. Chen, Francis S. Markland, Radu O. Minea, Stephen D. Swenson
  • Publication number: 20160317610
    Abstract: A method of treating ovarian cancer (OC) includes administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising vicrostatin and/or a protein substantially similar to vicrostatin. The administration is preferably performed intraperitoneally. The methods may include concurrently or sequentially administering to the patient one or more additional treatments for ovarian cancer. A pharmaceutical composition used in connection with the methods of the present invention comprise vicrostatin loaded in a viscoelastic gel comprising polyethylene oxide (PEO) and carboxymethyl cellulose (CMC).
    Type: Application
    Filed: September 25, 2014
    Publication date: November 3, 2016
    Applicant: University of Southern California
    Inventors: Francis S. MARKLAND, JR., Stephen D. Swenson, Radu O. Minea
  • Patent number: 8802394
    Abstract: Provided herein are methods for expressing proteins with disulfide bridges such as Vicrostatin (VCN), a chimeric variant of native snake venom disintegrin Contortrostatin (CN). The methods include what is believed to be a more efficient natural selection process that results in generating increased amounts of correctly-folded active conformers of proteins with disulfide bridges. In an aspect, this is achieved by growing Origami B cells in a more optimal redox environment during the induction of heterologous recombinant protein production.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: August 12, 2014
    Inventors: Radu O. Minea, Stephen D. Swenson, Francis S. Markland, Jr.
  • Publication number: 20120142603
    Abstract: Provided herein are compositions and methods for treating soft tissue injuries using a patch having a polymer on its surface linked to polypeptides having a disintegrin domain. The polypeptides having a disintegrin domain can include contortrostatin, vicrostatin, and ADAM derived polypeptides. Compositions of the invention can be used for the treatment of injuries to soft tissues that include the eye, liver and brain.
    Type: Application
    Filed: February 12, 2010
    Publication date: June 7, 2012
    Inventors: Francis S. Markland, Stephen D. Swenson, Radu O. Minea
  • Publication number: 20110300579
    Abstract: Provided herein are methods for expressing proteins with disulfide bridges such as Vicrostatin (VCN), a chimeric variant of native snake venom disintegrin Contortrostatin (CN). The methods include what is believed to be a more efficient natural selection process that results in generating increased amounts of correctly-folded active conformers of proteins with disulfide bridges. In an aspect, this is achieved by growing Origami B cells in a more optimal redox environment during the induction of heterologous recombinant protein production.
    Type: Application
    Filed: November 12, 2009
    Publication date: December 8, 2011
    Applicant: University of Southern California
    Inventors: Radu O. Minea, Stephen D. Swenson, Francis S. Markland, JR.
  • Patent number: 6214594
    Abstract: A size modified fibrinolytic enzyme, wherein the size of the enzyme is modified by covalent attachment of at least one large organic molecule to the enzyme.
    Type: Grant
    Filed: May 6, 1999
    Date of Patent: April 10, 2001
    Assignee: University of California
    Inventors: Francis S. Markland, Stephen D. Swenson